Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids

Respiratory Medicine

Volumn 97, Issue 9, 2003, Pages 1061-1066

  Ståhl, Elisabeth ^a,b   Postma, Dirkje S ^c   Svensson, Klas ^b   Tattersfield, Anne E ^d   Eivindson, Arne ^e   Schreurs, Ad ^f   Löfdahl, Claes Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e Havblik Medical Center   (Norway)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

As needed; Asthma; Formoterol; Health related quality of life

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; FORMOTEROL; TERBUTALINE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0041880647     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)00138-0     Document Type: Article

References (20)

1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
2. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet L-P, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995;151:66-70.
3. Wenzel SE, Lumry W, Cox FM, Manning M, Kalberg C, Emmett A, Rickard KA. Efficacy, safety and effects on quality of life salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allerg Asthma Immunol 1998;80:463-70.
4. Lockey RF, DuBuske LM, Cox FM, Friedman B, Petrocella V, Emmett A, Bowers B, Rickard KA. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999;115:666-73.
5. Busse WW, Casale TB, Murray JJ, Petrocella V, Rickard KA, Cox FM. Efficacy, safety and the impact on quality of life of salmeterol in patients with moderate, persistent asthma. Am J Manag Care 1998;4:1579-87.
6. Kemp JP, Cook DA, Cox FM, Incaudo GA, Corren J, Kalberg C, Emmett A, Rickard KA. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. J Allerg Clin Immunol 1998;101:188-95.
7. Maesen FP, Smeets SJ, Costongs MA, Zweers PG, Pfeil JP. Onset of action of eformoterol by dry powder inhaler; objective and subjective measures. Br J Clin Pract 1995;49: 294-6.
8. Linsen VMJ, Bindels HJC, van Noord JA. A direct comparison of the time of onset of action between inhaled formoterol and salmeterol. Eur Respir J 1996;9:1684-8.
9. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-9.
10. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998;92:1017-21.
11. Maesen F, Costongs R, Smeets J, Brombacher P, Zweers P. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991;99:1367-73.
12. Lstvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 μg (9 μg delivered). Eur Respir Dis 1997; 10(suppl 25):103s.
13. Tattersfield A, Löfdahl CG, Postma DS, Eivindson A, Schreurs A, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001;357:257-61.
14. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81-7.
15. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomized trials. Br Med J 1998;316:690-3.
16. Weersink EJ, van Zomeren EH, Koeter GH, Postma DS. Treatment of nocturnal airway obstruction improves cognitive performance in asthmatics. Am J Respir Crit Care Med 1997;156:1144-50.
17. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Löfdahl C-G, Postma DS, Pauwels RA, Tattersfield AE, Ullman A. Asthma quality of life during one year of treatment with budesonide with or without formoterol. Eur Resp J 1999; 14:1038-43.
18. Van der Molen T, Postma DS, Schreurs AJM, Bosveld HEP, Sears MR, Meyboom de Jong B. Discriminative aspects of two generic and two asthma specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma. Quality of Life Res 1997;6:353-61.
19. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147:832-8.
20. Juniper EF. Quality of life considerations in the treatment of asthma. Pharmacoeconomics 1995;8(2):123-38.